ArticleWorld journal of virology2025
Micro RNAs as a potential biomarker for predicting liver fibrosis severity in hepatitis C virus affected patients.
Article in World journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Evaluation of serum MicroRNAs and HCV Core antigen as predictive and diagnostic biomarkers for chronic hepatitis C management in Iraqi patients: comparison with PCR-based detection.Journal, genetic engineering & biotechnology · 2026Article
- miR-34a and miR-223 as diagnostic biomarkers for the severity of non-alcoholic fatty liver disease.Journal, genetic engineering & biotechnology · 2026Article
- Unifying and unique roles of non-coding RNA biomarkers in liver and heart fibrosis.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2026Review
- Plasma miRNA-Metabolite Dysregulation in People with HIV with Cirrhosis Despite Successful HCV Cure.Pharmaceuticals (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis C virus (HCV) infection process of progression encompasses multiple stages, commencing with inflammation and culminating in hepatocellular cancer. Numerous invasive and non-invasive procedures exist for diagnosing chronic HCV infection. Though beneficial, invasive procedures can cause morbidity and inadequate representation of the overall degree of fibrosis. Due to these reasons, non-invasive liver fibrosis biomarkers are becoming more prevalent to diagnose and track liver fibrosis without a liver biopsy. These biomarkers can detect liver fibrosis early, improving treatment and preventing cirrhosis and liver failure. Micro ribonucleic acid (MiRNA) dysregulation causes and worsens several diseases including liver disease. MiRNAs can facilitate the diagnosis of liver fibrosis and serve as a predictive tool to enhance patient care by minimizing invasive procedures and enabling more efficient and prompt therapy.
aimTo investigate the diagnostic effectiveness of several miRNAs (miRNA-122, miRNA-21, miRNA-199a, miRNA-155) in assessing the liver fibrosis severity in untreated HCV patients from the Indian Punjab population. We seek to identify the intricate diagnostic relationship of miRNAs with the extent of fibrosis among individuals with HCV.
methodsWe considered 100 persons determined as HCV infected by a quantitative Real-Time Polymerase Chain Reaction examination. We employed statistical as well as probabilistic tools to ascertain the diagnostic validity of miRNAs for determining the liver fibrosis stages. We employed Bayesian Networks, to introduce a unique diagnostic paradigm for miRNAs that can be adopted as benchmark to evaluate the liver fibrosis severity in HCV cases.
resultsWe found that miRNAs (miR-122, miR-155 and miR-21) showed significant upregulation when compared with control and according to severity of fibrosis (
conclusionDepending on the diagnostic accuracy, we have concluded that miR-122, miR-155 and miR-21 are reliable markers to detect fibrosis in Hepatitis C patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.